mdxhealth Rising momentum for a dedicated prostate cancer play
Today we issue a new flash note on mdxhealth, a dedicated player in the field of molecular diagnostics tools for prostate cancer and urology. The company has been gaining momentum in the past few months, driven by long-awaited final LCD coverage for its Select mdx test, the acquisition of the commercial-stage Oncotype DX GPS test from Exact Sciences for up to $ 100m and promising 1H22 results. We therefore maintain our recently upgraded PT at € 1.5 and reiterate a Buy rating.MDxHealth is a molecular diagnostics company that develops and commercializes epigenetic assays and service testing for cancer assessment and the personalized treatment of patients. Co. offers two main products: Clinical Molecular Diagnostics (ClinicalMDx) Solutions that provide physicians with tests for the identification and treatment of their cancer patients; and Pharmaco Molecular Diagnostics (PharmacoMDx) Solutions for the development of companion diagnostics, biomarker discovery, and clinical trial testing. Co.'s ClinicalMDx solutions include ConfirmMDx, InformMDx, RecurMDx, and PredictMDx.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.